Comparative Pharmacology
Head-to-head clinical analysis: WYAMYCIN E versus ZITHROMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WYAMYCIN E versus ZITHROMAX.
WYAMYCIN E vs ZITHROMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Azithromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by preventing translocation of peptides. It also has immunomodulatory and anti-inflammatory effects.
500 mg intramuscularly or intravenously every 12 hours; or 1 gram every 24 hours for severe infections.
500 mg orally once daily for 3 days, or 2 g orally as a single dose for certain infections.
None Documented
None Documented
2.5 hours (increased to 5-8 hours in neonates and up to 24-48 hours in anuria).
Terminal elimination half-life of approximately 68 hours (range 35-96 hours), allowing once-weekly dosing for some indications.
Primarily renal (60-80% unchanged) via glomerular filtration; biliary/fecal <5%.
Primarily eliminated via biliary/fecal route (∼50-60% as unchanged drug); renal excretion accounts for ∼12% of the dose; minimal metabolism.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic